EcoPhage Expands into Mexico with GoldenEco and EcoFire Distribution Agreement
Bacteriophages are moving beyond experimental crop-protection studies and into commercial distribution networks. EcoPhage has signed an agreement with Agricultura Nacional, S.A. de C.V., better known in Mexico under its Dragon brand, for the distribution, marketing and sale of two phage-based agricultural products across the country.
Announced on October 14, 2026, the agreement initially covers GoldenEco and EcoFire, two biological crop-protection products developed by EcoPhage to target bacterial diseases affecting economically important fruit and vegetable crops. Dragon will be responsible for establishing the products within the Mexican agricultural market and developing access through its national commercial network.
The financial terms of the agreement were not disclosed. EcoPhage also did not announce sales-volume commitments or a precise commercial launch date. Dragon's position as distribution partner is described as being subject to agreed commercial targets.
More importantly, the announcement should not be interpreted as confirmation that GoldenEco or EcoFire have obtained every regulatory authorization required for commercial sale in Mexico. The companies announced a distribution arrangement and commercialization strategy, but the release does not identify a Mexican regulatory approval, registration number or completed national authorization for either product.
That distinction is important because the agreement represents a concrete step toward commercialization rather than evidence that Mexican growers can already purchase and use the products without further regulatory steps.
The partnership is nevertheless significant for the emerging agricultural phage sector. Much of the attention around bacteriophages has focused on their potential as alternatives or complements to antibiotics in human medicine. Agriculture provides another potentially large application because many important crop diseases are caused by bacteria for which growers have relatively limited treatment options.
Unlike conventional broad-spectrum pesticides, bacteriophages are viruses that infect specific bacteria. They recognize susceptible bacterial cells, introduce their genetic material and use the host's machinery to produce new viral particles. Lytic phages ultimately destroy the infected bacterium and release progeny capable of infecting additional susceptible cells.
That specificity is both an advantage and a challenge.
A phage can target a plant pathogen while having little or no direct activity against unrelated microorganisms. This creates the possibility of suppressing particular bacterial diseases without applying a broadly toxic chemical treatment across the entire microbial community associated with a crop.
At the same time, narrow host range means that phage selection becomes critical. A bacteriophage active against one strain of a plant pathogen may not necessarily infect another. Commercial products therefore generally rely on carefully selected phages or cocktails designed to cover the bacterial diversity encountered in agricultural populations.
EcoPhage has built its development strategy around that problem. Founded in 2018, the Israeli agricultural biotechnology company uses a phage discovery and characterization platform co-developed with the Weizmann Institute of Science. Environmental phages are screened against target plant pathogens and evaluated according to factors including host range, stability, genomic characteristics and infection properties before candidates are incorporated into formulations.
GoldenEco is currently the company's most advanced commercial product. It is designed for bacterial diseases affecting tomatoes and peppers, particularly bacterial spot associated with Xanthomonas and bacterial speck caused by Pseudomonas syringae pv. tomato.
These diseases can significantly reduce crop quality and yield. Symptoms can develop on leaves, stems and fruits, and disease management becomes particularly difficult when environmental conditions favour bacterial multiplication and dissemination.
Copper-based products have historically played an important role in managing bacterial crop diseases, but repeated application can select for copper-tolerant bacterial populations. Copper accumulation and environmental considerations also create incentives to develop complementary approaches rather than depending on a single antimicrobial strategy.
GoldenEco uses naturally occurring bacteriophages selected to infect the bacterial pathogens responsible for these diseases. EcoPhage recommends the product as part of crop-protection programmes rather than presenting phages as a universal replacement for every existing treatment.
The company's current product information describes GoldenEco as a foliar formulation for tomatoes and peppers. Multiple applications are intended to maintain phage activity on plant surfaces during periods when crops remain vulnerable to bacterial infection.
This requirement illustrates an important difference between agricultural and medical phage therapy. In a field, bacteriophages are exposed directly to environmental conditions that can reduce their viability. Ultraviolet radiation, temperature, desiccation, rainfall and the chemical environment of the leaf surface can all influence how long active phage particles remain available after application.
Formulation is therefore a major technological component of agricultural phage development. Identifying a virus capable of killing the pathogen in laboratory culture is only the first step. The product must also retain sufficient activity during manufacturing, storage, transport, dilution, spraying and exposure on the crop.
EcoPhage says it has invested in formulation and agronomic research alongside phage discovery for precisely this reason. The company has reported field testing of GoldenEco in several agricultural environments, including Mexico.
In earlier company-reported Mexican trials, GoldenEco was tested against bacterial diseases of tomatoes at multiple locations and was reported to achieve disease-control performance exceeding 50% across the growing cycle and to compare favourably with the copper-based programme used as the reference treatment.
Those results provide useful background for the new distribution agreement because the product has already been evaluated under Mexican agricultural conditions. They should nevertheless be interpreted cautiously. The figures were released by EcoPhage rather than presented as results from a peer-reviewed, independently replicated agronomic study, and they do not by themselves establish regulatory approval or expected commercial performance across Mexico.
GoldenEco reached another development milestone shortly before the Mexican agreement. In September 2026, EcoPhage announced that the product had received approval from the U.S. Environmental Protection Agency for use against bacterial diseases in tomatoes and peppers.
That authorization applies to the United States and should not be extrapolated to Mexico. Regulatory approval of agricultural biological products is jurisdiction-specific, and the October agreement does not state that U.S. EPA approval automatically provides or substitutes for Mexican authorization.
Nevertheless, the timing shows that EcoPhage is moving GoldenEco from product development toward multi-market commercialization.
On October 7, only a week before the Mexican announcement, EcoPhage also disclosed a non-exclusive U.S. distribution agreement with CNI AG for GoldenEco. The subsequent agreement with Dragon therefore forms part of a broader commercial expansion strategy rather than an isolated partnership.
The second product included in the Mexican agreement, EcoFire, addresses a different pathogen and crop system.
EcoFire is designed to control fire blight caused by Erwinia amylovora in apples and pears. Fire blight is one of the best-known bacterial diseases of rosaceous fruit trees and can rapidly damage blossoms, shoots, branches and, in severe cases, entire young trees.
The characteristic darkened and necrotic appearance of infected shoots gave the disease its name. Once established, E. amylovora can spread through plant tissues and between trees, with insects, rain and agricultural operations contributing to dissemination.
Management typically combines preventive practices, removal of infected tissue and antimicrobial treatments where these are legally available. Antibiotic use against plant pathogens is permitted in some jurisdictions but highly restricted in others, while resistance has reduced the effectiveness of particular compounds in some bacterial populations.
EcoFire applies the same broad biological principle as GoldenEco but uses phages selected against E. amylovora. EcoPhage describes it as a foliar bactericide for apple and pear production containing a proprietary combination of naturally occurring bacteriophages.
Using cocktails rather than individual phages can serve several purposes. Combining viruses with different receptor dependencies can increase the fraction of bacterial strains susceptible to the product and make it more difficult for a pathogen population to escape treatment through a single resistance mutation.
This is particularly relevant in agricultural environments where bacterial populations can be genetically heterogeneous and where repeated treatment may generate strong evolutionary pressure.
Phage resistance does not disappear simply because viruses rather than chemicals are being used. Bacteria can modify or lose phage receptors, alter extracellular structures and deploy intracellular antiviral systems capable of restricting infection.
A well-designed cocktail therefore needs more than several arbitrary phages mixed together. Its components should ideally provide complementary host ranges or infection mechanisms so that resistance against one component does not automatically protect the bacterium against the others.
EcoPhage says its discovery platform considers these characteristics during candidate selection and uses genomic and phenotypic analysis to assemble cocktails from its broader phage collections.
The commercial partnership with Dragon is notable because distribution is one of the practical steps that laboratory-focused phage projects often do not reach.
Agricultural biological products need more than efficacy. They require manufacturing at sufficient scale, stable formulation, regulatory documentation, reliable storage and transportation, integration into growers' treatment schedules, technical support and distribution networks capable of reaching farming regions at the correct point in the season.
Agricultura Nacional provides EcoPhage with an established partner for this downstream component.
Dragon traces its agricultural activities to 1935 and describes itself as a Mexican company involved in crop protection and nutrition. Its operations include formulation, commercialization and nationwide distribution, with distribution centres in several parts of Mexico.
The company's existing portfolio covers insect control, weed control, plant diseases, crop nutrition and other agricultural applications. Its distribution network therefore places EcoPhage's technology inside an organization already accustomed to selling and supporting crop-protection products rather than requiring the Israeli biotechnology company to construct its own Mexican commercial infrastructure.
Dragon CEO Martin Fueyo Mac Donald said in the companies' announcement that the partnership would allow Dragon to introduce EcoPhage's phage technology into the Mexican agricultural market as demand grows for more sustainable crop-protection solutions.
EcoPhage CEO Guy Elitzur framed Mexico as part of a broader commercialization strategy and said the relationship could eventually support additional EcoPhage technologies and products beyond the two initially included in the agreement.
That potential future expansion is relevant because EcoPhage's pipeline is already broader than GoldenEco and EcoFire.
The company is also developing EcoStonia, targeting Moko disease of bananas, a destructive bacterial wilt associated with the Ralstonia solanacearum species complex. In July 2026, EcoPhage and Dole announced work involving phage-based approaches against Moko disease, illustrating another potential large-scale agricultural application for the platform.
The Mexican agreement could therefore function as more than a distribution route for two existing products. If the partnership performs commercially and future products obtain the required regulatory clearances, the same Dragon network could potentially provide an entry point for additional phage-based crop-protection technologies.
This platform approach is strategically important because the economics of agricultural phages differ from highly personalized medical phage therapy.
A human therapeutic programme may sometimes match individual phages against bacterial isolates from specific patients. Agricultural products generally need to work reproducibly across large crop areas and against bacterial populations encountered by many different growers.
Commercial agricultural phage products therefore tend toward standardized formulations and defined pathogen targets, allowing manufacturing, distribution and application practices to become more conventional.
That does not eliminate biological complexity. Bacterial populations can vary geographically and seasonally, phage stability can depend heavily on local environmental conditions, and the effectiveness of foliar application depends on factors such as timing, disease pressure, weather and integration with other crop-protection practices.
Mexico is particularly interesting in this context because its agricultural production spans very different climates and growing systems. A product performing well in one region or season cannot automatically be expected to produce identical results elsewhere.
Large-scale commercialization therefore generates evidence that controlled research alone cannot provide. Repeated use across farms can reveal whether formulations remain effective under diverse conditions, how application programmes integrate with existing practices and whether bacterial resistance emerges during prolonged field deployment.
Post-commercial surveillance and resistance monitoring may consequently become as important for phage-based agricultural products as they are for conventional antimicrobial strategies.
Another question concerns compatibility with integrated pest management.
Phages are unlikely to operate in isolation from other agricultural products. Growers may combine them with fungicides, insecticides, biological agents or other bactericides as part of broader disease-management programmes.
Compatibility matters because some tank-mixed compounds or environmental conditions could potentially reduce phage viability. Product-specific testing is therefore necessary before assuming that a bacteriophage formulation can simply be combined with any conventional treatment.
EcoPhage positions GoldenEco as compatible with a range of agricultural products and as a potential tool for reducing dependence on copper. As with other performance claims, compatibility needs to be considered according to the tested formulations and use conditions rather than generalized to every possible combination.
The environmental argument for agricultural phages is nevertheless compelling enough to drive substantial interest.
Bacteriophages are already ubiquitous in soil, water and plant-associated microbial communities. A crop-protection formulation based on naturally occurring phages can therefore use biological interactions that already take place in agricultural ecosystems.
Their narrow target specificity may reduce direct effects on unrelated bacteria compared with broad-spectrum antimicrobials. However, environmental safety still requires formal assessment because commercial application changes the concentration, composition and timing of phage exposure compared with natural conditions.
Regulators consequently evaluate phage-based biopesticides as products rather than assuming that natural origin automatically guarantees safety.
The same caution applies to claims around bacterial resistance. Phages can potentially help diversify antimicrobial pressure and provide alternatives where resistance to copper compounds or antibiotics is problematic, but bacteria can evolve resistance to phages as well.
One potential advantage is that bacteriophages can themselves evolve. Developers can isolate new phages, reformulate cocktails or potentially replace components when bacterial populations change.
This adaptability is attractive scientifically but creates regulatory and manufacturing questions. A conventional pesticide generally has a fixed active ingredient. A phage cocktail may benefit biologically from periodic adaptation, but changing one viral component could potentially affect its regulatory identity, manufacturing controls and commercial registration.
How regulators manage such updates may become increasingly important as phage products expand in agriculture.
The EcoPhage–Dragon agreement is therefore interesting beyond the two named products. It provides another example of phage technology beginning to encounter the practical realities of conventional crop-protection markets: regulatory approvals, distributor relationships, commercial targets, farmer adoption and integration with established agricultural practices.
This represents a different stage from the many phage projects that remain focused on discovering new viruses or demonstrating antibacterial activity in laboratory assays.
It is also different from announcing a successful clinical or agronomic trial. The October 14 agreement provides evidence of commercial intent and distribution infrastructure, not new independent evidence that GoldenEco or EcoFire will control disease under every Mexican growing condition.
Financial terms were not disclosed, no projected revenue or sales volume was announced, and the companies did not specify when the first commercial Mexican applications will occur.
Most importantly, the announcement does not identify Mexican regulatory authorization for either product. Until such authorization and market-launch details are confirmed, the agreement should be understood as preparation for market distribution rather than proof that nationwide commercial use is already underway.
Still, commercial partnerships matter because phage technology can have little agricultural impact if it never progresses beyond experimental plots.
GoldenEco's recent U.S. regulatory milestone, the U.S. distribution agreement announced in early October and now the partnership with Agricultura Nacional indicate that EcoPhage is attempting to build the distribution layer needed to turn its bacteriophage platform into an international crop-protection business.
Mexico provides an important test of that strategy.
If GoldenEco and EcoFire successfully progress through the remaining market-access requirements and gain adoption among growers, they could provide another demonstration that bacteriophages are capable of moving from microbiology laboratories into routine agricultural disease management.
For the phage field, that transition is worth watching closely. Human phage therapy continues to confront complex clinical and regulatory challenges, while agricultural applications may provide a parallel route through which standardized phage products can be manufactured, distributed and used at scale.
The EcoPhage–Dragon agreement does not yet prove that this commercial model will succeed. It does show that agricultural phage development is increasingly entering a stage where the central questions are no longer only whether phages can kill plant pathogens, but whether those biological products can navigate regulation, distribution and real-world agricultural adoption across major markets.
Sources :
EcoPhage — “EcoPhage and Agricultura Nacional Sign a Distribution Agreement for Mexico,” October 14, 2026. The announcement confirms the agreement with Agricultura Nacional/Dragon, the initial inclusion of GoldenEco and EcoFire, Dragon's responsibility for Mexican marketing and distribution, and the fact that the partnership is subject to agreed commercial targets.
EcoPhage — Mexico distribution announcement
EcoPhage — GoldenEco product information. The company describes GoldenEco as a foliar phage-based product targeting bacterial spot and speck in tomatoes and peppers and provides information on its intended agricultural application programme.
EcoPhage — EcoFire product information. EcoFire is described as a phage-based product targeting Erwinia amylovora, the causative agent of fire blight in apple and pear production.
EcoPhage — “EcoPhage Receives U.S. EPA Approval for GoldenEco,” September 2026. This concerns the United States only and does not establish Mexican regulatory authorization.
EcoPhage — GoldenEco U.S. EPA announcement
EcoPhage — GoldenEco field testing in Mexico. EcoPhage previously reported trials conducted by a local CRO at different Mexican locations, with company-reported disease-control performance exceeding 50% over the growing cycle. These figures come from the company and should not be treated as independent peer-reviewed validation.
EcoPhage — GoldenEco field trials in Mexico
Agricultura Nacional / Dragon — Company profile and distribution network. Dragon describes more than 85 years of experience in agricultural formulation, distribution and commercialization and a distribution network covering Mexico.
Dragon — About Agricultura Nacional
EcoPhage — Technology platform and pipeline. EcoPhage describes its phage-screening platform, co-developed with the Weizmann Institute of Science, and its GoldenEco, EcoFire and EcoStonia programmes.
.png){kind=logo}
Comments
Post a Comment